Vice President, Preclinical Operations
Michael has contributed substantially to the development of Athenex’s clinical pipeline, operations, and platform technologies, including the Optimized PhotoAffinity Labelling (OPAL) platform technology which is a keystone to Athenex’s drug discovery efforts today. As the Company’s primary chemist since 2008, he has made significant contributions to Athenex’s clinical pipeline through hands-on research and management of IND-enabling studies including many aspects of drug substance, product, and process development.
Prior to joining Athenex, Michael completed a postdoctoral position at Scripps Florida where he focused on the drug discovery of kinase inhibitors, which resulted in several patent applications and publications. Michael obtained his PhD from SUNY University at Buffalo, and his multi-disciplinary PhD thesis on the “Thermodynamics of Molecular Recognition” contained breakthrough findings for the biotechnology industry.